Steven E. Finkelstein, M.D., DABR, FACRO

May 20, 2024 — Associated Medical Professionals of NY (A.M.P.) announced that internationally recognized radiation oncology physician, researcher and thought leader Steven E. Finkelstein, M.D., DABR, FACRO, has joined its care team as Director of the Center of Advanced Radiation Excellence (CARE) and Director of Radiation Oncology Research.

Associated Medical Professionals of NY spans 18 locations in Central New York, including nine offices and nine hospitals. A.M.P. Radiation Oncology is the region’s leading provider of comprehensive cancer care services, providing the most advanced, effective treatments available for urological and other types of cancers. A.M.P. is an affiliate of U.S. Urology Partners, one of the largest independent providers of urological and specialty related services in the nation, which is backed by NMS Capital.

Dr. Finkelstein has treated thousands of patients with prostate cancer and genitourinary malignancies, been principal investigator for groundbreaking clinical trials, and continues contributing to prestigious scientific journals with over 11,000 literature citations with an H-Index of 42. Additionally, he is renowned in bladder, kidney and testicular cancer as well as lung, breast and skin cancers which he will also treat at A.M.P. Dr. Finkelstein is passionate about leadership in organized medicine and is a strong advocate for physicians and the patients they serve. He is a graduate of the University of Michigan, where he completed his medical degree, and spent his residency at Moffitt Cancer Center and fellowship at the National Cancer Institute, National Institutes of Health. Dr. Finkelstein has been recognized as a Castle Connolly Top Doctor for five years in a row.

Corina Tracy, Chief Executive Officer of U.S. Urology Partners, stated, “Dr. Steven Finkelstein’s extensive experience in radiation oncology care and his leadership in the medical field will be a tremendous asset to U.S. Urology Partners, Associated Medical Professionals of NY and most importantly to individuals receiving cancer care in the Central New York region. Dr. Finkelstein’s dedication will further our mission to provide the best treatment available to our patients in the most compassionate way utilizing the most advanced, proven technology for every person we are privileged to serve.”

Christopher M. Pieczonka, M.D., Chief Executive Officer of Associated Medical Professionals of NY and Corporate Director of Clinical Research of U.S. Urology Partners, stated, “The Central New York community has long been the geographic heart of New York State and is on the cusp of a significant population influx from the construction and opening of Micron Technology Inc. We have recruited Dr. Steven Finkelstein for his prowess and expertise in providing cutting-edge clinical research in all aspects of radiation oncology to our patients. Currently Associated Medical Professionals is running over 30 active clinical trials, and we anticipate exponential growth with Dr Finkelstein’s expertise.”

Steven E. Finkelstein, M.D., DABR, FACRO, stated, “I am passionate about advancing patient care for all and committed to outstanding cancer care providing access to today’s leading-edge technologies and innovative treatment options. I am excited to join the team of Associated Medical Professionals of NY and look forward to helping patients in the community.”

For more information: www.us-uro.com


Related Content

News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Remanufactured Refurbished Equipment

Jan. 11, 2026 — The Global Refurbished Medical Imaging Equipment Market Size is projected to grow at a CAGR of 15.07% ...

Time January 23, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
News | Interventional Radiology

Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...

Time November 13, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
Subscribe Now